연구동향 분석

Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine

김현석 백순명 성여진 2015년

논문상세정보
인용/피인용
' Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의학
  • biomarker
  • cancer genomics
  • personalized medicine
  • targeted therapy
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
7,878 0

0.0%

' Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine' 의 참고문헌

  • siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens
    Singh NK Genomics Inform 11 : 55 ~ 57 [2013]
  • siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens
    Nitin Kumar Singh Genomics & Informatics 11 1 55-57 [2013]
  • Unresponsiveness of colon cancer to BRAF(V600E)inhibition through feedback activation of EGFR
    Prahallad A Nature 483 : 100 ~ 103 [2012]
  • Unresponsiveness of colon cancer to BRAF(V600E)inhibition through feedback activation of EGFR
    Prahallad A Nature 483 100-103 [2012]
  • Towards patient-based cancer therapeutics
    Cancer Target Discovery and Development Network Nat Biotechnol 28 : 904 ~ 906 [2010]
  • Towards patient-based cancer therapeutics
    Cancer Target Discovery and Development Network Nat Biotechnol 28 904-906 [2010]
  • The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe
    Epstein RJ. Front Oncol 3 : 304 ~ [2013]
  • The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe
    Epstein RJ. Front Oncol 3 304- [2013]
  • The hallmarks of cancer
    Hanahan D Cell 100 : 57 ~ 70 [2000]
  • The hallmarks of cancer
    Hanahan D Cell 100 57-70 [2000]
  • The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
    Abaan OD Cancer Res 73 : 4372 ~ 4382 [2013]
  • The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
    Abaan OD Cancer Res 73 4372-4382 [2013]
  • The NCI60 human tumour cell line anticancer drug screen
    Shoemaker RH Nat Rev Cancer 6 : 813 ~ 823 [2006]
  • The NCI60 human tumour cell line anticancer drug screen
    Shoemaker RH Nat Rev Cancer 6 813-823 [2006]
  • The Ludwig institute for cancer research Melbourne melanoma cell line panel
    Behren A Pigment Cell Melanoma Res 26 : 597 ~ 600 [2013]
  • The Ludwig institute for cancer research Melbourne melanoma cell line panel
    Behren A Pigment Cell Melanoma Res 26 597-600 [2013]
  • The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    Barretina J Nature 483 : 603 ~ 607 [2012]
  • The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    Barretina J Nature 483 603-607 [2012]
  • Systematic variation in gene expression patterns in human cancer cell lines
    Ross DT Nat Genet 24 : 227 ~ 235 [2000]
  • Systematic variation in gene expression patterns in human cancer cell lines
    Ross DT Nat Genet 24 227-235 [2000]
  • Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer
    Cheung HW Proc Natl Acad Sci U S A 108 : 12372 ~ 12377 [2011]
  • Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer
    Cheung HW Proc Natl Acad Sci U S A 108 12372-12377 [2011]
  • Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer
    Kim HS Cell 155 : 552 ~ 566 [2013]
  • Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer
    Kim HS Cell 155 552-566 [2013]
  • Systematic identification of genomic markers of drug sensitivity in cancer cells
    Garnett MJ Nature 483 : 570 ~ 575 [2012]
  • Systematic identification of genomic markers of drug sensitivity in cancer cells
    Garnett MJ Nature 483 570-575 [2012]
  • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    Barbie DA Nature 462 : 108 ~ 112 [2009]
  • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    Barbie DA Nature 462 108-112 [2009]
  • Synthetic lethal screen identification of chemosensitizer loci in cancer cells
    Whitehurst AW Nature 446 : 815 ~ 819 [2007]
  • Synthetic lethal screen identification of chemosensitizer loci in cancer cells
    Whitehurst AW Nature 446 815-819 [2007]
  • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
    Corcoran RB Cancer Cell 23 : 121 ~ 128 [2013]
  • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
    Corcoran RB Cancer Cell 23 121-128 [2013]
  • Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
    Scholl C Cell 137 : 821 ~ 834 [2009]
  • Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
    Scholl C Cell 137 821-834 [2009]
  • Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
    Sato T Nature 459 : 262 ~ 265 [2009]
  • Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
    Sato T Nature 459 262-265 [2009]
  • Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets
    Zaman N Cell Rep 5 : 216 ~ 223 [2013]
  • Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets
    Zaman N Cell Rep 5 216-223 [2013]
  • Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells
    Rheinwald JG Cell 6 : 331 ~ 343 [1975]
  • Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells
    Rheinwald JG Cell 6 331-343 [1975]
  • Secondgeneration shRNA libraries covering the mouse and human genomes
    Silva JM Nat Genet 37 1281-1288 [2005]
  • Second-generation shRNA libraries covering the mouse and human genomes
    Silva JM Nat Genet 37 : 1281 ~ 1288 [2005]
  • Regularization and variable selection via the elastic net
    Zou H J R Statist Soc B 67 : 301 ~ 320 [2005]
  • Regularization and variable selection via the elastic net
    Zou, H. J R Statist Soc B 67 301-320 [2005]
  • Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
    de Bruin EC Cancer Discov 4 : 606 ~ 619 [2014]
  • Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
    de Bruin EC Cancer Discov 4 606-619 [2014]
  • Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
    Gillet JP Proc Natl Acad Sci U S A 108 : 18708 ~ 18713 [2011]
  • Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
    Gillet JP Proc Natl Acad Sci U S A 108 18708-18713 [2011]
  • Rapid modelling of cooperating genetic events in cancer through somatic genome editing
    Sánchez-Rivera FJ Nature 516 : 428 ~ 431 [2014]
  • Rapid modelling of cooperating genetic events in cancer through somatic genome editing
    Sánchez-Rivera FJ Nature 516 428-431 [2014]
  • ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells
    Liu X Am J Pathol 180 : 599 ~ 607 [2012]
  • ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells
    Liu X Am J Pathol 180 599-607 [2012]
  • RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
    Lamba S Cell Rep 8 : 1475 ~ 1483 [2014]
  • RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
    Lamba S Cell Rep 8 1475-1483 [2014]
  • Quantitative phenotypic and pathway profiling guides rational drug combination strategies
    Dawson JC Front Pharmacol 5 : 118 ~ [2014]
  • Quantitative phenotypic and pathway profiling guides rational drug combination strategies
    Dawson JC Front Pharmacol 5 118- [2014]
  • Profiling essential genes in human mammary cells by multiplex RNAi screening
    Silva JM Science 319 : 617 ~ 620 [2008]
  • Profiling essential genes in human mammary cells by multiplex RNAi screening
    Silva JM Science 319 617-620 [2008]
  • Principles of cancer therapy: oncogene and non-oncogene addiction
    Luo J Cell 136 : 823 ~ 837 [2009]
  • Principles of cancer therapy: oncogene and non-oncogene addiction
    Luo J Cell 136 823-837 [2009]
  • Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
    Sos ML J Clin Invest 119 : 1727 ~ 1740 [2009]
  • Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
    Sos ML J Clin Invest 119 1727-1740 [2009]
  • Patient-derived models of acquired resistance can identify effective drug combinations for cancer
    Crystal AS Science 346 : 1480 ~ 1486 [2014]
  • Patient-derived models of acquired resistance can identify effective drug combinations for cancer
    Crystal AS Science 346 1480-1486 [2014]
  • Ovarian cancer cell line panel (OCCP):clinical importance of in vitro morphological subtypes
    Beaufort CM PLoS One 9 : e103988 ~ [2014]
  • Ovarian cancer cell line panel (OCCP):clinical importance of in vitro morphological subtypes
    Beaufort CM PLoS One 9 e103988- [2014]
  • Organoid models of human and mouse ductal pancreatic cancer
    Boj SF Cell 160 : 324 ~ 338 [2015]
  • Organoid models of human and mouse ductal pancreatic cancer
    Boj SF Cell 160 324-338 [2015]
  • Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
    Jia P Genome Res 23 : 1434 ~ 1445 [2013]
  • Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
    Jia P Genome Res 23 1434-1445 [2013]
  • NCI series of cell lines: an historical perspective
    Gazdar AF J Cell Biochem Suppl 24 : 1 ~ 11 [1996]
  • NCI series of cell lines: an historical perspective
    Gazdar AF J Cell Biochem Suppl 24 1-11 [1996]
  • Molecular target class is predictive of in vitro response profile
    Greshock J Cancer Res 70 : 3677 ~ 3686 [2010]
  • Molecular target class is predictive of in vitro response profile
    Greshock J Cancer Res 70 3677-3686 [2010]
  • Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery
    Kao J PLoS One 4 : e6146 ~ [2009]
  • Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery
    Kao J PLoS One 4 e6146- [2009]
  • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or NRAS upregulation
    Nazarian R Nature 468 : 973 ~ 977 [2010]
  • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or NRAS upregulation
    Nazarian R Nature 468 973-977 [2010]
  • Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?
    Gazdar AF Lung Cancer 68 : 309 ~ 318 [2010]
  • Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?
    Gazdar AF Lung Cancer 68 309-318 [2010]
  • Lung cancer cell lines as tools for biomedical discovery and research
    Gazdar AF J Natl Cancer Inst 102 : 1310 ~ 1321 [2010]
  • Lung cancer cell lines as tools for biomedical discovery and research
    Gazdar AF J Natl Cancer Inst 102 1310-1321 [2010]
  • Lessons from the cancer genome
    Garraway LA Cell 153 : 17 ~ 37 [2013]
  • Lessons from the cancer genome
    Garraway LA Cell 153 17-37 [2013]
  • JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs
    Kong D Bioorg Med Chem 20 : 1947 ~ 1951 [2012]
  • JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs
    Kong D Bioorg Med Chem 20 1947-1951 [2012]
  • Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
    Gao J Sci Signal 6 : pl1 ~ [2013]
  • Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
    Gao J Sci Signal 6 pl1- [2013]
  • Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel
    Bussey KJ Mol Cancer Ther 5 : 853 ~ 867 [2006]
  • Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel
    Bussey KJ Mol Cancer Ther 5 853-867 [2006]
  • Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer
    Liu J Nat Commun 5 : 3830 ~ [2014]
  • Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer
    Liu J Nat Commun 5 3830- [2014]
  • Inconsistency in large pharmacogenomic studies
    Haibe-Kains B Nature 504 : 389 ~ 393 [2013]
  • Inconsistency in large pharmacogenomic studies
    Haibe-Kains B Nature 504 389-393 [2013]
  • In vivo RNA interference screens identify regulators of antiviral CD4(+) and CD8(+) T cell differentiation
    Chen R Immunity 41 : 325 ~ 338 [2014]
  • In vivo RNA interference screens identify regulators of antiviral CD4(+) and CD8(+) T cell differentiation
    Chen R Immunity 41 325-338 [2014]
  • Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
    McDermott U Proc Natl Acad Sci U S A 104 : 19936 ~ 19941 [2007]
  • Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
    McDermott U Proc Natl Acad Sci U S A 104 19936-19941 [2007]
  • Highly parallel identification of essential genes in cancer cells
    Luo B Proc Natl Acad Sci U S A 105 : 20380 ~ 20385 [2008]
  • Highly parallel identification of essential genes in cancer cells
    Luo B Proc Natl Acad Sci U S A 105 20380-20385 [2008]
  • High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing
    Sims D Genome Biol 12 : R104 ~ [2011]
  • High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing
    Sims D Genome Biol 12 R104- [2011]
  • HeLa cells 50 years on: the good, the bad and the ugly
    Masters JR Nat Rev Cancer 2 : 315 ~ 319 [2002]
  • HeLa cells 50 years on: the good, the bad and the ugly
    Masters JR Nat Rev Cancer 2 315-319 [2002]
  • Hallmarks of cancer: the next generation
    Hanahan D Cell 144 646-674 [2011]
  • Hallmarks of cancer : the next generation
    Hanahan D Cell 144 : 646 ~ 674 [2011]
  • Global proteome analysis of the NCI-60 cell line panel
    Moghaddas Gholami A Cell Rep 4 : 609 ~ 620 [2013]
  • Global proteome analysis of the NCI-60 cell line panel
    Moghaddas Gholami A Cell Rep 4 609-620 [2013]
  • Glioma cells on the run - the migratory transcriptome of 10 human glioma cell lines
    Demuth T BMC Genomics 9 : 54 ~ [2008]
  • Glioma cells on the run - the migratory transcriptome of 10 human glioma cell lines
    Demuth T BMC Genomics 9 54- [2008]
  • Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
    Yang W Nucleic Acids Res 41 : D955 ~ D961 [2013]
  • Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
    Yang W Nucleic Acids Res 41 D955-D961 [2013]
  • Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen
    Mendes-Pereira AM Proc Natl Acad Sci U S A 109 : 2730 ~ 2735 [2012]
  • Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen
    Mendes-Pereira AM Proc Natl Acad Sci U S A 109 2730-2735 [2012]
  • Genome-scale CRISPR-Cas9 knockout screening in human cells
    Shalem O Science 343 : 84 ~ 87 [2014]
  • Genome-scale CRISPR-Cas9 knockout screening in human cells
    Shalem O Science 343 84-87 [2014]
  • Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events
    Liu J Genome Res 22 : 2315 ~ 2327 [2012]
  • Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events
    Liu J Genome Res 22 2315-2327 [2012]
  • Genetic screens in human cells using the CRISPR-Cas9 system
    Wang T Science 343 : 80 ~ 84 [2014]
  • Genetic screens in human cells using the CRISPR-Cas9 system
    Wang T Science 343 80-84 [2014]
  • Functional genomics identifies therapeutic targets for MYC-driven cancer
    Toyoshima M Proc Natl Acad Sci U S A 109 : 9545 ~ 9550 [2012]
  • Functional genomics identifies therapeutic targets for MYC-driven cancer
    Toyoshima M Proc Natl Acad Sci U S A 109 9545-9550 [2012]
  • Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer
    Martens-de Kemp SR Clin Cancer Res 19 : 1994 ~ 2003 [2013]
  • Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer
    Martens-de Kemp SR Clin Cancer Res 19 1994-2003 [2013]
  • Evaluating cell lines as tumour models by comparison of genomic profiles
    Domcke S Nat Commun 4 : 2126 ~ [2013]
  • Evaluating cell lines as tumour models by comparison of genomic profiles
    Domcke S Nat Commun 4 2126- [2013]
  • Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features
    Dangles-Marie V Cancer Res 67 : 398 ~ 407 [2007]
  • Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features
    Dangles-Marie V Cancer Res 67 398-407 [2007]
  • Establishment and characterization of primary lung cancer cell lines from Chinese population
    Zheng C Acta Pharmacol Sin 32 : 385 ~ 392 [2011]
  • Establishment and characterization of primary lung cancer cell lines from Chinese population
    Zheng C Acta Pharmacol Sin 32 385-392 [2011]
  • Essential gene profiles in breast, pancreatic, and ovarian cancer cells
    Marcotte R Cancer Discov 2 : 172 ~ 189 [2012]
  • Essential gene profiles in breast, pancreatic, and ovarian cancer cells
    Marcotte R Cancer Discov 2 172-189 [2012]
  • Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
    Arumugam T Cancer Res 69 : 5820 ~ 5828 [2009]
  • Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
    Arumugam T Cancer Res 69 5820-5828 [2009]
  • Epigenetic and genetic features of 24 colon cancer cell lines
    Ahmed D Oncogenesis 2 : e71 ~ [2013]
  • Epigenetic and genetic features of 24 colon cancer cell lines
    Ahmed D Oncogenesis 2 e71- [2013]
  • Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel
    Shen L Cancer Res 67 : 11335 ~ 11343 [2007]
  • Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel
    Shen L Cancer Res 67 11335-11343 [2007]
  • Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
    Hollestelle A Breast Cancer Res Treat 121 : 53 ~ 64 [2010]
  • Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
    Hollestelle A Breast Cancer Res Treat 121 53-64 [2010]
  • Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm
    Paull KD J Natl Cancer Inst 81 : 1088 ~ 1092 [1989]
  • Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm
    Paull KD J Natl Cancer Inst 81 1088-1092 [1989]
  • Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
    Ashraf SQ Proc Natl Acad Sci U S A 109 : 21046 ~ 21051 [2012]
  • Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
    Ashraf SQ Proc Natl Acad Sci U S A 109 21046-21051 [2012]
  • Development and applications of CRISPR-Cas9 for genome engineering
    Hsu PD Cell 157 : 1262 ~ 1278 [2014]
  • Development and applications of CRISPR-Cas9 for genome engineering
    Hsu PD Cell 157 1262-1278 [2014]
  • Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations
    Dan S Cancer Res 70 : 4982 ~ 4994 [2010]
  • Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations
    Dan S Cancer Res 70 4982-4994 [2010]
  • Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Jones S Science 321 : 1801 ~ 1806 [2008]
  • Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Jones S Science 321 1801-1806 [2008]
  • Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer
    Gazdar AF Int J Cancer 78 : 766 ~ 774 [1998]
  • Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer
    Gazdar AF Int J Cancer 78 766-774 [1998]
  • Cell lines used in prostate cancer research: a compendium of old and new lines--part 2
    Sobel RE J Urol 173 : 360 ~ 372 [2005]
  • Cell lines used in prostate cancer research: a compendium of old and new lines--part 2
    Sobel RE J Urol 173 360-372 [2005]
  • Cell lines used in prostate cancer research: a compendium of old and new lines--part 1
    Sobel RE J Urol 173 : 342 ~ 359 [2005]
  • Cell lines used in prostate cancer research: a compendium of old and new lines--part 1
    Sobel RE J Urol 173 342-359 [2005]
  • Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
    Sharma SV Nat Rev Cancer 10 : 241 ~ 253 [2010]
  • Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
    Sharma SV Nat Rev Cancer 10 241-253 [2010]
  • Cell culture methods for the establishment of the NCI series of lung cancer cell lines
    Oie HK J Cell Biochem Suppl 24 : 24 ~ 31 [1996]
  • Cell culture methods for the establishment of the NCI series of lung cancer cell lines
    Oie HK J Cell Biochem Suppl 24 24-31 [1996]
  • Cancer proliferation gene discovery through functional genomics
    Schlabach MR Science 319 : 620 ~ 624 [2008]
  • Cancer proliferation gene discovery through functional genomics
    Schlabach MR Science 319 620-624 [2008]
  • COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
    Forbes SA Nucleic Acids Res 39 : D945 ~ D950 [2011]
  • COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
    Forbes SA Nucleic Acids Res 39 D945-D950 [2011]
  • Breast cancer cell lines: friend or foe?
    Burdall SE Breast Cancer Res 5 : 89 ~ 95 [2003]
  • Breast cancer cell lines: friend or foe?
    Burdall SE Breast Cancer Res 5 89-95 [2003]
  • Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines
    Liu Y Proc Natl Acad Sci U S A 103 : 976 ~ 981 [2006]
  • Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines
    Liu Y Proc Natl Acad Sci U S A 103 976-981 [2006]
  • An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules
    Basu A Cell 154 : 1151 ~ 1161 [2013]
  • An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules
    Basu A Cell 154 1151-1161 [2013]
  • An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
    Byers LA Clin Cancer Res 19 : 279 ~ 290 [2013]
  • An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
    Byers LA Clin Cancer Res 19 279-290 [2013]
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    Pao W PLoS Med 2 : e73 ~ [2005]
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    Pao W PLoS Med 2 e73- [2005]
  • AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
    Cross DA Cancer Discov 4 : 1046 ~ 1061 [2014]
  • AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
    Cross DA Cancer Discov 4 1046-1061 [2014]
  • A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
    Turner NC EMBO J 27 : 1368 ~ 1377 [2008]
  • A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
    Turner NC EMBO J 27 1368-1377 [2008]
  • A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis
    Kranz D EMBO J 33 : 181 ~ 197 [2014]
  • A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis
    Kranz D EMBO J 33 181-197 [2014]
  • A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik S N Engl J Med 351 : 2817 ~ 2826 [2004]
  • A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik S N Engl J Med 351 2817-2826 [2004]
  • A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells
    Petrocca F Cancer Cell 24 : 182 ~ 196 [2013]
  • A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells
    Petrocca F Cancer Cell 24 182-196 [2013]
  • A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
    Luo J Cell 137 : 835 ~ 848 [2009]
  • A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
    Luo J Cell 137 835-848 [2009]
  • A gene-alteration profile of human lung cancer cell lines
    Blanco R Hum Mutat 30 : 1199 ~ 1206 [2009]
  • A gene-alteration profile of human lung cancer cell lines
    Blanco R Hum Mutat 30 1199-1206 [2009]
  • A community effort to assess and improve drug sensitivity prediction algorithms
    Costello JC Nat Biotechnol 32 : 1202 ~ 1212 [2014]
  • A community effort to assess and improve drug sensitivity prediction algorithms
    Costello JC Nat Biotechnol 32 1202-1212 [2014]
  • A colorectal cancer classification system that associates cellular phenotype and responses to therapy
    Sadanandam A Nat Med 19 : 619 ~ 625 [2013]
  • A colorectal cancer classification system that associates cellular phenotype and responses to therapy
    Sadanandam A Nat Med 19 619-625 [2013]
  • A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Neve RM Cancer Cell 10 : 515 ~ 527 [2006]
  • A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Neve RM Cancer Cell 10 515-527 [2006]
  • A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays
    Zhang JH J Biomol Screen 4 : 67 ~ 73 [1999]
  • A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays
    Zhang JH J Biomol Screen 4 67-73 [1999]
  • A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis
    Kessler JD Science 335 : 348 ~ 353 [2012]
  • A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis
    Kessler JD Science 335 348-353 [2012]
  • 50 years of preclinical anticancer drug screening: empirical to target-driven approaches
    Suggitt M Clin Cancer Res 11 : 971 ~ 981 [2005]
  • 50 years of preclinical anticancer drug screening: empirical to target-driven approaches
    Suggitt M Clin Cancer Res 11 971-981 [2005]